Navigation Links
Data From Two Phase 3 Studies Show Anti-TNF Golimumab Significantly Improved Signs and Symptoms of Rheumatoid Arthritis
Date:6/11/2008

endpoint was based on an intent-to-treat (ITT) analysis, which included all patients randomized in the study. However, three patients did not receive study drug but were included in the analysis as nonresponders. In the primary analysis of the combined group of patients receiving either golimumab 50 mg or 100 mg in combination with MTX, 38 percent (40 percent receiving 50 mg and 37 percent receiving 100 mg) achieved at least 50 percent improvement in signs and symptoms of RA (ACR 50) through week 24, compared with 29 percent of patients receiving placebo plus MTX (p=0.053 for the combined group, p=0.042 for 50 mg and p=0.177 for 100 mg). When the three patients who did not receive golimumab were excluded in a modified intent-to-treat (mITT) analysis, the results showed that 39 percent of patients in the combined golimumab plus MTX group (41 percent receiving 50 mg and 37 percent receiving 100 mg) achieved ACR 50, compared with 29 percent of patients receiving placebo plus MTX (p=0.049 for the combined group, p=0.038 for 50 mg and p=0.177 for 100 mg). Additionally, 62 percent of patients in the combined golimumab plus MTX group (62 percent for each dose group) achieved ACR 20, compared with 49 percent receiving placebo plus MTX (p=0.011 for the combined group and p=0.028 for each dose group).

"These data show that treatment with golimumab induces an important depth of response, improving multiple aspects of rheumatoid arthritis and leading to significant decreases in disease activity," said Roy Fleischmann, M.D., Clinical Professor, Department of Internal Medicine at the University of Texas Southwestern Medical Center; Chief, Division of Rheumatology at St. Paul University Hospital in Dallas, Texas and lead study investigator. "Golimumab, which is an anti-TNF therapy, is a promising treatment option for multiple patient populations with this chronic and potentially debilitating inflammatory disease."

Also at week 24, patients receiving golimumab plus MT
'/>"/>

SOURCE Centocor
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
3. Progen Engages Leading CRO to Assist with Phase 3 Trial of PI-88
4. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
5. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
6. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
7. Positive Kuvan(TM) Pivotal Phase 3 Trial Results Published in The Lancet
8. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
9. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
10. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
11. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2015)... -- Object recognition technology has a unique and powerful ... VelaSense ® mobile platform incorporates applications ... and fulfilling lives. VelaSense ® will now incorporate ... objects from a one million object database, that is ... for personal use. Visus Technology ...
(Date:3/27/2015)... 2015  Holographic Optical Technologies of Augusta, ... medical imaging, is entering the world of consumer electronics ... April 20 th , 2015, the campaign will introduce ... and 22-inch displays will allow consumers to view fully ... In addition to the two displays, the company will ...
(Date:3/27/2015)... March 27, 2015   Cypher Genomics, Inc., ... new data showing that, compared to a panel ... provided highly equivalent interpretations of whether certain genetic ... so in a fraction of the time. Cypher,s ... more comprehensive genetic analysis in non-invasive prenatal testing ...
Breaking Medicine Technology:VelaSense Object Recognition Technology for the Blind was unveiled at Baruch College's CCVIP 8th Annual Conference 2Holographic Optical Technologies brings cutting-edge holograms to consumer market through upcoming Kickstarter campaign 2Holographic Optical Technologies brings cutting-edge holograms to consumer market through upcoming Kickstarter campaign 3New Data at ACMG Shows Cypher's Software Can Automate Interpretation of Genetic Variants to Advance Non-invasive Prenatal Testing 2New Data at ACMG Shows Cypher's Software Can Automate Interpretation of Genetic Variants to Advance Non-invasive Prenatal Testing 3
... (Nasdaq: PRXL ) announced today it will be presenting ... York, NY. James Winschel, Senior Vice President and Chief ... at 3:30 p.m. EDT on Tuesday, October 6, 2009. , ... the "Upcoming Events" section on PAREXEL,s "Investors" homepage at ...
... HERZELIYA, Israel, September 30 ... an investment round led by 7 Health,Ventures. Previous ... the round as well. , ... guidance systems used,in Computer Tomography (CT), fluoroscopy and ...
Cached Medicine Technology:PAREXEL International to Present at William Blair Emerging Growth Stock Conference 2
(Date:3/28/2015)... Could genetic code determine someone’s coffee ... by researchers at the Harvard T.H. Chan School ... of the Coffee and Caffeine Genetics Consortium and ... fall, the study—one of several recent HSPH investigations of ... more than 120,000 regular coffee drinkers of European and ...
(Date:3/28/2015)... (PRWEB) March 28, 2015 With ... in the fields of osteoporosis, osteoarthritis and musculoskeletal ... Osteoporosis, it may be the first time in ... research forum that the hot-button topic is an ... on the well-accepted scientific principles of Wolff’s law, ...
(Date:3/28/2015)... March 28, 2015 Emergency Medical Care ... care in Manhattan, recently commemorated its three-year anniversary of ... Manhattan. In addition to 24-hour urgent care, Emergency Medical ... , At this time, Emergency Medical Care’s Urgent ... asthma, chest pain, eye injuries, ear infections, fevers, insect ...
(Date:3/28/2015)... Centurion Service Group will be hosting a live on-site ... their Las Vegas warehouse, located at 4606 Andrews St. Suite ... of equipment from hospitals and surgery centers from around the ... , Buyers will find items of all types including anesthesia, ... said Erik Tivin, CEO of Centurion. , Among the sale’s ...
(Date:3/28/2015)... How best to treat and recover from ... medicine. While diagnostic hip injections are commonly performed for ... research presented today at the American Orthopaedic Society for ... pain relief from this diagnostic injection may not predict ... study looked to assess if the amount of pain ...
Breaking Medicine News(10 mins):Health News:How Coffee Habits Relate to Our Genetic Code and Enhancing the Caffeine Experience 2Health News:How Coffee Habits Relate to Our Genetic Code and Enhancing the Caffeine Experience 3Health News:Non-Drug Protocol for Building Bone Density Expected to Steal Spotlight at World Congress on Osteoporosis 2Health News:Emergency Medical Care Celebrates Three Years of 24/7 Walk-In Urgent Care Services 2Health News:Medical Equipment Auction to Take Place in North Las Vegas 2Health News:Pain Injections for Hip Arthroscopy Patients May Not Predict Surgical Outcomes 2
... lead the global angiography, fluoroscopy and X-ray business , , ... the new CEO of Siemens Healthcare,s U.S. ... position, Reitermann will lead the marketing, sales and service functions for ... medical imaging, therapy and health care information technology businesses. He ...
... the first effective treatment in the fight against malaria ... this devastating disease. But the drug is associated with a ... and headaches to blindness, deafness and in rare cases death ... at The University of Nottingham have made a discovery that ...
... Texas, June 29 The physicians of Hematology-Oncology ... provider community based specialty practice caring for adults with cancers ... agreement with Oncology Pharmaceutical Services (OPS) ... support of an oncology-trained consultant pharmacist. , , By ...
... Couple, Clovis Students Win Thousands of Dollars in Milk Contest ... struggle month after month with Premenstrual Syndrome, a.k.a. man,s worst ... of whom do not yet know that milk could be ... an effort to educate women on the PMS-fighting benefits of ...
... ... on Drug Abuse (VIDA) working in collaboration with colleagues at Vector Tobacco, Inc. and Duke ... better chance at kicking the tobacco habit. , ... Manhasset, NY (Vocus) June 29, 2009 -- Scientists at the ...
... Corporation (Nasdaq: AIRM ), the largest air medical ... a petition with the National Transportation Safety Board (NTSB) requesting ... June 29, 2008 mid-air collision accident in Flagstaff, Arizona. ... to see and avoid the other helicopter on approach to ...
Cached Medicine News:Health News:Michael Reitermann to Head Siemens Healthcare U.S. Organization 2Health News:Breakthrough in combating the side effects of quinine 2Health News:Oncology Group's Pharmaceutical Services Agreement Enhances Efficiency of Drug Management Program 2Health News:Oncology Group's Pharmaceutical Services Agreement Enhances Efficiency of Drug Management Program 3Health News:No More Drama With TOMA LECHE 2Health News:No More Drama With TOMA LECHE 3Health News:No More Drama With TOMA LECHE 4Health News:News from the Latest Issue of Molecular Medicine Kicking The Habit - It's In The Genes 2Health News:Air Methods Petitions NTSB for Reconsideration of Probable Cause Determination 2
... solution tricompartmental total knee prosthesis stems from ... State-of-the-art design and manufacturing technologies have been ... function as well as a favorable pressure ... to keep wear to a minimum. The ...
... was designed for patients with difficult problems ... custom designs to repair difficult anatomic conditions. ... which reduces the chance of dislocation in ... been streamlined and updated so that the ...
The design and concept of the Alpina knee allows the choice of implanting a PCL retaining or a posterior stabilized prosthesis intraoperatively....
... knee prosthesis stems from many years of ... manufacturing technologies have been used in order ... as a favorable pressure distribution pattern on ... to a minimum. The inherent design of ...
Medicine Products: